BioSpace News Archive

Business

Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress

In the three months ended Sept. 30, 2017 and 2016, we recognized $1.9 million and $1.3 million, respectively, of revenue associated with our Pfizer collaboration.

November 7, 2017

·

11 min read

Business

Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B

Spark Therapeutics to receive up to an additional $25 million per terms of amendment.

November 7, 2017

·

8 min read

Business

Repligen Extends Long Term Supply Agreement With Purolite for Protein A Ligands

Pursuant to the agreement, Repligen will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025.

November 7, 2017

·

4 min read

Business

Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update

For the third quarter of 2017, the company’s total revenue was less than $0.1 million, which compares with $1.0 million for the third quarter of 2016.

November 7, 2017

·

16 min read

Drug Development

ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase IIb Clinical Trial of OBE2109 for the Treatment of Endometriosis

Approximately 330 patients are expected to be randomized in the EDELWEISS clinical trial, and primary endpoint efficacy results continue to be anticipated in mid-2018.

November 7, 2017

·

5 min read

FDA

U.S. FDA Approves Keryx Biopharma’s Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis

Auryxia is the only oral treatment option available today developed and approved specifically for adults living with iron deficiency anemia and chronic kidney disease, not on dialysis.

November 7, 2017

·

9 min read

Business

Genovis Signs Distribution Agreement With Shanghai Titan Scientific Ltd.

A growing number of companies in China are focusing on biopharma, at the same time that global pharmaceutical companies are locating their process development and production in the area.

November 7, 2017

·

1 min read

Business

Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results

Approximately 24,900 Auryxia prescriptions were written in the third quarter of 2017, representing 18 percent growth over the second quarter of 2017.

November 7, 2017

·

12 min read

Business

Antares Pharma Reports Third Quarter 2017 Operating and Financial Results

The Company reported record revenue of $15.1 million and a net loss per share of $0.03 for the three months ended September 30, 2017.

November 7, 2017

·

12 min read

Policy

Noven Files Patent Infringement Lawsuit Against Alvogen

Alvogen is seeking approval to market and sell a generic version of Minivelle (estradiol transdermal system) prior to the expiration of two of Noven’s Orange Book listed patents (U.S. Patent Nos. 9724310 and 9730900).

November 7, 2017

·

1 min read